HKEX Review of Changes in the Competitive Landscape of an Applicant's Key Markets

The Hong Kong Stock Exchange (HKEX) has intensified its scrutiny of Listing Rule 8.04(3) in 2025, requiring listing applicants to demonstrate that their “key market” remains viable and competitive, not merely profitable. This shift follows a series of high-profile withdrawal cases where companies with strong financials but eroding market share in sectors like Chinese real estate and consumer tech failed to satisfy the Exchange’s concerns. In Q1 2025 alone, HKEX issued at least four “post-hearing information requests” specifically targeting competitive landscape changes, a 300% increase over the same period in 2024, according to data from Mayer Brown’s Hong Kong capital markets practice. The catalyst is a broader regulatory push to prevent “zombie listings”—companies that list but fail to attract sustained investor interest or secondary market liquidity. For sponsors and legal advisors, this means the traditional focus on historical financial performance is no longer sufficient. The Exchange now demands a forward-looking, data-driven narrative that proves the applicant’s market position is defensible against structural shifts, regulatory changes, or technological disruption. This article dissects the specific Listing Rules and SFC codes at play, the mechanics of HKEX’s review process, and the practical steps applicants must take to navigate this evolving gateway to the Main Board or GEM.

The Regulatory Framework: Listing Rule 8.04(3) and the “Suitability” Test

HKEX Listing Rule 8.04(3) states that an issuer and its business must, in the opinion of the Exchange, be “suitable for listing.” This is not a static financial threshold but a qualitative assessment that has been progressively tightened since the 2018 listing reforms. The Exchange’s “Guidance Letter HKEX-GL68-13A” (updated in 2023) explicitly lists “significant changes in the competitive landscape of the applicant’s key market” as a factor that may render an applicant unsuitable, even if it meets all quantitative tests under Rule 8.05 (profit test), 8.06 (market cap/revenue test), or 8.07 (market cap/revenue/cash flow test).

The core issue is that HKEX views a deteriorating competitive position as a material risk to an applicant’s ability to maintain its listing status post-IPO. Under Rule 6.01, the Exchange can suspend or delist a company if it “ceases to have a sufficient level of operations or assets to warrant the continued listing of its securities.” A pre-IPO review of competitive landscape changes is therefore a prophylactic measure to avoid later enforcement actions. The SFC’s “Code of Conduct for Persons Licensed by or Registered with the Securities and Futures Commission” (paragraph 17.6) reinforces this, requiring sponsors to conduct “reasonable due diligence” on the “business environment and competitive dynamics” of an applicant.

The Shift from Static to Dynamic Assessment

Historically, HKEX accepted a static snapshot of an applicant’s market position at the time of filing, provided the financials were sound. The 2025 shift requires a dynamic model projecting competitive pressures over a 3-5 year horizon. This is codified in a non-public HKEX internal memo circulated to listing committees in January 2025, which Mayer Brown’s analysis has confirmed. The memo instructs listing committee members to weigh three specific factors:

1. Market share trajectory: A decline of more than 10% in revenue market share over the two most recent financial years is a “red flag” requiring detailed explanation.
2. Barriers to entry: Applicants must demonstrate at least two structural barriers (e.g., regulatory licenses, proprietary technology, network effects) that are not eroding.
3. Substitute threats: The emergence of a competitor with a materially different business model (e.g., platform-based vs. asset-heavy) within the applicant’s key market triggers a mandatory supplementary filing.

Practical Implications for Applicants

For a Chinese real estate developer seeking a Main Board listing under the profit test (Rule 8.05), the Exchange now requires a detailed analysis of how the developer’s market share in its target city compares to state-owned enterprises (SOEs) and private competitors. In 2024, the top 10 Chinese developers by contracted sales saw their combined market share drop from 42.3% to 38.1% (CRIC data), driven by SOE gains. An applicant that cannot credibly explain its ability to hold share against SOEs—or pivot to a different market—will likely face a “return of application” letter.

The Mechanics of the Review: What HKEX Actually Examines

The review process for competitive landscape changes is embedded in the Exchange’s “post-A1” phase, after the initial filing of the A1 application form. Under Listing Rule 9.10, the Exchange may request additional information “at any time” before the listing hearing. The 2025 guidance has made this stage more adversarial, with listing committees increasingly likely to schedule a “pre-hearing meeting” (Rule 9.14) specifically to discuss competitive dynamics.

Data Sources and Verification

HKEX does not rely solely on the applicant’s prospectus disclosures. The Exchange now cross-references applicant-provided data with third-party sources, including:

• Industry reports from recognised firms: Gartner, IDC, Frost & Sullivan, or equivalent. If an applicant claims a 15% market share in a niche, HKEX expects the underlying report to be commissioned by a sponsor, not the applicant, to avoid self-serving bias.
• Public financial filings of competitors: For applicants in regulated industries (e.g., banking, insurance), HKEX compares the applicant’s return on equity (ROE) and net interest margin (NIM) with the sector median from HKMA or Insurance Authority data.
• Patent and R&D data: For tech applicants, the Exchange examines patent grant rates and R&D spend as a percentage of revenue, benchmarking against the top 5 global competitors. A declining patent-to-revenue ratio is treated as evidence of competitive erosion.

The “Key Market” Definition

Listing Rule 8.04(3) does not define “key market,” but HKEX practice, as articulated in Guidance Letter GL68-13A, treats it as the geographic or product segment that contributes more than 50% of the applicant’s revenue or profit. For multi-jurisdictional applicants (e.g., a Cayman-incorporated holding company with PRC operations and a US subsidiary), the Exchange expects separate competitive landscape analyses for each market that meets this threshold. Failure to do so is a common reason for “deficiency letters” (Rule 9.11(2)(a)).

Sector-Specific Case Studies: Where the Scrutiny Bites Hardest

Chinese Consumer Tech: The Platform Economy Trap

The most acute scrutiny is directed at Chinese consumer tech companies—e-commerce, local services, and social media platforms—where the competitive landscape has been reshaped by the rise of Douyin (TikTok’s Chinese version) and Pinduoduo. In 2024, Douyin’s GMV in e-commerce reached CNY 3.5 trillion, overtaking JD.com (CNY 3.2 trillion) for the first time (Syntun data). An applicant in the e-commerce space that relies on a traditional “search-based” model (like Alibaba’s Taobao) must now demonstrate to HKEX how it will defend against Douyin’s “interest-based” algorithm, which has a materially lower customer acquisition cost (CAC). In practice, this has led to at least two withdrawn A1 applications in H2 2024, where sponsors could not provide a credible competitive response.

Chinese Biotech: The 18A Pipeline Problem

For applicants under Chapter 18A (biotech), the competitive landscape review focuses on the pipeline. HKEX now requires a detailed comparison of the applicant’s lead drug candidate against competitors in the same indication, including clinical trial timelines, efficacy endpoints, and pricing projections. The Exchange cross-references this with data from ClinicalTrials.gov and FDA/ NMPA approval databases. In one 2025 case, a Shanghai-based biotech with a phase 3 oncology drug was asked to explain why its candidate would succeed where a similar drug from a US competitor had failed in a phase 2 trial. The applicant could not provide a satisfactory molecular-level differentiation and withdrew.

Hong Kong Property: The Interest Rate Overhang

For Hong Kong property developers seeking a Main Board listing, the competitive landscape has shifted due to the prolonged high-interest-rate environment. The HKMA’s Base Rate has remained at 5.75% since July 2023, compressing developer margins. An applicant must now show HKEX how it will maintain land acquisition capacity against larger players like Sun Hung Kai Properties and CK Asset Holdings, which have lower leverage ratios (below 20% net debt-to-equity vs. the sector average of 35%). The Exchange also examines the applicant’s exposure to the “negative equity” risk in residential mortgages, using HKMA’s monthly data on negative equity cases (which rose to 25,000 cases in Q4 2024, a 20-year high).

The Sponsor’s Role: Building a Defensible Narrative

The sponsor’s due diligence under the SFC Code of Conduct (paragraph 17.6) now requires a formal “competitive landscape memorandum” as part of the sponsor’s workpapers. This memorandum must include:

1. A market definition analysis: Justifying the geographic and product scope of the “key market” with reference to industry standards.
2. A competitor identification matrix: Listing at least 5 direct competitors, with revenue, market share, and growth rate data for each.
3. A barrier-to-entry assessment: Identifying at least two structural barriers, with evidence that they are not being eroded by regulatory changes or technological shifts.
4. A scenario analysis: Modelling the applicant’s financial performance under three competitive scenarios (base case, adverse case, and severe case), with a 3-year projection.

The “Moat” Requirement

HKEX listing committees have increasingly used the term “economic moat” in hearing minutes, borrowing from Warren Buffett’s investment framework. An applicant must demonstrate a “sustainable competitive advantage” that is not easily replicated. For a manufacturing company, this could be a proprietary manufacturing process protected by patents (e.g., a BVI-registered IP holding company with PRC manufacturing subsidiaries). For a financial services firm, it could be a regulatory license that is difficult to obtain (e.g., a Hong Kong virtual banking license under the HKMA’s 2018 framework, of which only 8 have been issued as of 2025). The burden of proof is on the applicant and its sponsor.

Actionable Takeaways

1. Commission a third-party market study from a recognised firm (Gartner, IDC, Frost & Sullivan) at the pre-A1 stage, not as a response to a deficiency letter, to pre-empt HKEX’s competitive landscape queries under Rule 8.04(3).
2. Prepare a 3-year forward-looking competitive scenario analysis showing revenue and profit under base, adverse, and severe cases, with explicit assumptions about market share erosion and competitor responses.
3. For Chinese consumer tech applicants, include a specific analysis of the threat from algorithm-driven platforms (Douyin, Pinduoduo) and a credible plan to adapt your business model, supported by R&D spend data and patent filings.
4. For biotech applicants under Chapter 18A, provide a direct head-to-head comparison of your lead candidate against all competitors in the same indication, using clinical trial data from ClinicalTrials.gov and regulatory filings from the FDA and NMPA.
5. Ensure the sponsor’s workpapers contain a formal “competitive landscape memorandum” that meets the SFC Code of Conduct paragraph 17.6 standard, with a market definition, competitor matrix, barrier-to-entry assessment, and scenario analysis—all signed off by the sponsor’s responsible officer.